Knowledge, Skill and Passion Drives the Company Culture.
The BioArdis team centers around core philosophies that are essential to its company's steadfast success: scientific expertise, entrepreneurial spirit and a strong sense of family cohesiveness. At the core of the team is decades of experience in the life sciences, spanning all aspects of drug discovery and development, in both small molecules and large molecules.
The founders and team members have worked together in a multitude of capacities over the years. A great deal of trust and understanding supported by the strong sense of a family culture is near and dear to the hearts of all. The team has a deep history of building successful companies, across several countries, not only in the life sciences, but also in information technology, finance and real estate.
BioArdis is committed to bringing lifesaving therapies into the clinic and supporting partners as they advance them to approval.
Dr. Masood Tayebi is a Founding Partner and the CEO of the Bridgewest Group
. He has a wealth of experience commercializing new technology, particularly in pharmaceutical and biotechnology sectors, as well as the wireless communications sectors. Dr Tayebi is directly responsible for managing Bridgewest investments in biotechnology and pharmaceuticals, hi-tech and wireless technologies, and software.
He has successfully founded many companies, including a global wireless communications service company, a disruptive semiconductor IP technology company, and a CRO company with over 1,000 employees with operations in the USA and China. Dr Tayebi has been integral in the success of multiple public and private companies alongside his brother, Dr. Massih Tayebi.
Ian Wisenberg, Chief Business Officer
Ian Wisenberg has more than 35 years’ experience in international business with an emphasis in finance, capital formation and business development. He is one of the founders and Chief Business Officer of BioArdis. He transitioned to his new role from Chief Financial Officer at BioDuro after its sale to Advent International in early 2019.
Previously, Ian ran a very successful consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad.
Ian is from Cape Town, South Africa, and attended the University of Cape Town.
Frank Kayser, Ph.D., CSO
Frank Kayser spearheads all aspects of small molecule discovery at BioArdis. With expertise in medicinal chemistry and structure-based drug design, Frank has developed numerous candidates for neuroscience, cardiovascular disease, metabolic disorders, oncology, and immunology. He has led multidisciplinary teams that progressed compounds from early chemical leads into optimized clinical candidates, including multiple Ph2 and Ph1 clinical compounds.
Previously, Frank was Senior VP Chemistry for Integrated Programs at BioDuro. Additionally, he’s held research and management positions in the pharmaceutical industry at Merck, Tularik and Amgen.
Frank is a co-author on more than 40 peer-reviewed publications as well as an inventor of more than 40 US-issued and corresponding international patents, and multiple pending US and PCT applications. Frank has a Ph.D. in Chemistry at the University of Marburg, Germany with Prof. M. T. Reetz, and a Postdoctoral fellowship with Prof. B. H. Lipshutz at the University of California, Santa Barbara.
Farzad Haerizadeh, Ph.D., Executive Vice President Biologics and Cell Therapy
Farzad Haerizadeh oversees and manages large molecule and cell therapy pipelines and programs at BioArdis.
Farzad has more than 20 years of experience in the life sciences and biotech industries with a strong focus on adaptive cellular and immuno-oncology products including CAR-T, allogeneic CAR-T, allogeneic ‘off the shelf’ stem cell/iPSC products, mammalian genome editing and synthetic biology. In the past several years he served as the VP of preclinical IO platform development in F1Oncology/ Exuma Inc.
He also held multiple key R&D roles in several pharma/biotech companies such as Intrexon, Synthetic Genomics, Life Technologies Corporation (Thermifisher Scientific) and Codexis Inc. where he initiated and directed multiple cutting-edge adaptive cell therapy (engineering T cells, T cell receptors (TCRs), NK cells) and therapeutics discovery platforms, xenotransplantation, protein engineering and industrial enzymes evolution programs. He is also experienced in bio-manufacturing and product development.
Farzad holds a PhD and a postdoctoral fellowship in Molecular, Cellular & Systems Biology from the University of Melbourne, Australia, and a postdoctoral fellowship from Stanford University, California.
Helena Jiang, Director Program Management and Site Head, BioArdis China
Helena (Liqun) Jiang brings over 17 years of industry R & D and management experience in drug discovery programs to BioArdis. Her vast experience includes target validation, assay development and validation, SAR funnel development, compound screening and MoA studies for various target families and disease areas. Helena is responsible for program management and supervising BioArdis operations in China.
She has managed hundreds of projects for pharmaceutical/biotech companies in the US, Europe and China resulting in value-added contributions to their pipelines while working for leading companies including Adlai Nortye, BioDuro and HD Biosciences.
Helena’s education includes a Master of Science in Cellular and Molecular in biology from Peking Union Medical College, graduate school work and Research Associate with University of Texas at Austin, and an Executive MBA from University of Plymouth.
BioArdis Advisory Team
Simon Bailey, Ph.D., Advisor
Simon Bailey’s distinguished career draws on over twenty years of experience in pharmaceutical/bioscience during which he has lead drug discovery and medicinal chemistry teams in oncology, metabolic diseases and fibrosis therapeutic areas. In addition to his Advisory role at BioArdis, he is Head of Drug Discovery at Plexium Pharmaceuticals.
Formerly, Simon held the positions of SVP of Research for Intercept Pharmaceuticals and Department Head of Oncology Medicinal Chemistry at Pfizer. At Pfizer, he led projects from inception to Phase 1a and served as the head of diabetes medicinal chemistry.
Simon led or was a member of teams that discovered 18 clinical candidates, including the NSCLC ALK inhibitors Loratinib and Crizotinib. He co-authored more than 30 papers, obtained numerous patents and has chaired international conference sessions. Simon has a Ph.D. in Chemistry from the University of Manchester (UK) and an MBA from the University of California at San Diego, Rady School of Management.
Lawrence R. McGee, Ph.D., Advisor
Lawrence McGee’s noteworthy career stems more than 35 years in drug discovery and medicinal chemistry at prominent companies such as DuPont Central Research, Genentech, Gilead Sciences, Tularik, and Amgen. Lawrence has directed multiple groups on projects in Oncology, Inflammation, Metabolic Disorders and Heart Failure. Clinical candidates include T131, AMG925, AMG232, AMG319, AMG357, AMG397 and AMG986.
Lawrence is an author of more than 30 peer-reviewed publications and an inventor on more than 50 US-issued and corresponding international patents and multiple pending US and PCT applications.
Lawrence has a Ph.D. in Chemistry from the California Institute of Technology, Pasadena, Ca with Prof. David A. Evans.